Table 4.
Analysis of the clinical, biological, and genetic characteristics previously selected by predictive analytics statistical methods, which better contributed to prediction the grade of tumor regression (Dworak grade) after RCT, was administrated prior to surgery.
| Variables | Importance Ranking by Method | Median Ranking | ||||
|---|---|---|---|---|---|---|
| Boruta | Xgboost | Relative Importance | DALEX | VITA | ||
| N2 | 2 | 7 | 1 | 3 | 1 | 2 |
| N1 | 4 | 5 | 4 | 4 | 3 | 4 |
| chr4q loss | 3 | 1 | 3 | 1 | 2 | 2 |
| chr15q11.1 gain | 5 | 4 | 2 | 2 | 5 | 4 |
| chr17q21.31 gain | 1 | 2 | 5 | 6 | 7 | 5 |
| chr15q14 loss | 7 | 3 | 7 | 5 | 6 | 6 |
| CEA | 6 | 6 | 6 | 7 | 4 | 6 |
N1: presence of tumor involvement in 1 to 3 perirectal lymph node; N2: presence of tumor involvement in ≥4 perirectal lymph nodes. CEA: carcinoembryonic antigen determined at diagnosis. The best position of the variable to predict the response to the RCT administrated prior to surgery is shown in bold.